Novo Nordisk

COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk on Wednesday lifted its sales and operating profit forecasts for the year on the back of strong ...

Overall, sales of obesity drugs grew 83% in the second quarter compared to the same period last year. The growth is driven by increasing demand for GLP-1 based diabetes treatments, especially Ozempic," Chief Executive Lars Fruergaard Jorgensen said in a statement. The company had initially planned to announce results on Thursday.

Novo Nordisk, which employs more than 1600 workers in North Carolina, is looking to hire as many as 200 more staff - and soon.

“We remain committed to being a responsible business leader and demonstrating our commitment to increasing the talent pipeline with our local higher education partners,” Henry told WRAL TechWire in an interview. The company expanded to a second facility in Clayton in 2016, where it operates an active pharmaceutical ingredients production facility. In 2019, the company acquired the Durham facility, which Henry said will package the API manufactured at the Clayton facilities, thereby closing the loop in production such that it will “create a U.S.-to-U.S. production of oral GLP-1 tablets for the treatment for Type 2 diabetes for the U.S. market.” That’s led to needing to hire more talented workers to the company’s largest manufacturing footprint in all of the United States, said Henry. According to Chad Henry, corporate vice president and general manager, the company now employs more than 1,600 workers in North Carolina, an increase of 900 employees in the last six years, or an average of 150 net new workers hired each year. DURHAM – Despite an increasing number of layoffs sweeping through North Carolina last month, Novo Nordisk is looking to hire workers across the Triangle, including employees that would be based in its two Clayton facilities, an executive outlined to WRAL TechWire.

The Danish pharmaceutical company posted a net profit of 27.53 billion Danish kroner ($3.76 billion) in the first half, from DKK24.75 billion in the same period ...

Reported growth in sales is now seen around nine percentage points higher than in local currencies from seven percentage points higher previously, while reported operating-profit growth is seen around 14 percentage points higher from around 11 percentage points higher previously. Full-year guidance was raised, with the company now expecting 2022 sales growth of 12%-16% from 10%-14% previously, and operating-profit growth of 11%-15% from 9%-13%, both measured in local currencies. Novo Nordisk AS said Wednesday that its first-half sales and profit both rose on increasing demand for diabetes treatments, and it raised its 2022 outlook for sales and operating profit growth.

Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion. Sales in International Operations ...

On 3 August 2022 at 19.30 CEST, corresponding to 1.30 pm EDT, an earnings call will be held. The performance in the first six months has enabled us to raise our outlook for the full year." H1 2022

By Joe Hoppe Novo Nordisk AS said Wednesday that its first-half sales and profit both rose on increasing demand for diabetes treatments, and it raised its.

Reported growth in sales is now seen around nine percentage points higher than in local currencies from seven percentage points higher previously, while reported operating-profit growth is seen around 14 percentage points higher from around 11 percentage points higher previously. Full-year guidance was raised, with the company now expecting 2022 sales growth of 12%-16% from 10%-14% previously, and operating-profit growth of 11%-15% from 9%-13%, both measured in local currencies. The Danish pharmaceutical company posted a net profit of 27.53 billion Danish kroner ($3.76 billion) in the first half, from DKK24.75 billion in the same period last year.

Novo Nordisk (NYSE: NVO). Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion.

On 3 August 2022 at 19.30 CEST, corresponding to 1.30 pm EDT, an earnings call will be held. The performance in the first six months has enabled us to raise our outlook for the full year." H1 2021 - Within R&D, Novo Nordisk has now successfully completed five phase 3a trials with insulin icodec, a long-acting once-weekly insulin. H1 2022 - Sales in International Operations increased by 15% in Danish kroner (10% at CER), and sales in North America Operations increased by 36% in Danish kroner (24% at CER).

Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion. Sales in International Operations increased ...

We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. The performance in the first six months has enabled us to raise our outlook for the full year." On 3 August 2022 at 19.30 CEST, corresponding to 1.30 pm EDT, an earnings call will be held. - Within R&D, Novo Nordisk has now successfully completed five phase 3a trials with insulin icodec, a long-acting once-weekly insulin. - Sales within Diabetes and Obesity care increased by 28% in Danish kroner to DKK 72.7 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 57% in Danish kroner (45% at CER). Rare disease sales increased by 6% measured in Danish kroner (unchanged at CER).

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter...

The results did not meet Wall Street expectations. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVO at https://www.zacks.com/ap/NVO BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion.

After a contract manufacturing snafu in December, supply of Novo Nordisk's GLP-1 med for obesity appears to back on track in the U.S.—mostly.

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion. On a per-share basis, the Bagsvaerd, ...

The results did not meet Wall Street expectations. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVO at https://www.zacks.com/ap/NVO BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion.

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion. On a per-share basis, the Bagsvaerd, ...

The results did not meet Wall Street expectations. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVO at https://www.zacks.com/ap/NVO BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion.

Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in ...

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter...

The results did not meet Wall Street expectations. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVO at https://www.zacks.com/ap/NVO BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $1.91 billion.

By Dominic Chopping Novo Nordisk AS reported results for the second quarter late Wednesday. Here's what we watched: NET PROFIT: Net profit in the quarter...

Reported growth in sales is now seen around nine percentage points higher than in local currencies from around seven percentage points higher previously, and reported operating profit growth is now seen around 14 percentage points higher from around 11 percentage points higher. --GUIDANCE: Novo Nordisk raised guidance, saying it now expects 2022 sales growth of 12%-16% from 10%-14% previously, and operating profit growth of 11%-15% from 9%-13% in local currencies. --MARGINS: The 2Q gross margin was 85.3% compared with 83.2% in the same period last year. --GLUCAGON-LIKE PEPTIDE-1: Sales of Novo Nordisk's glucagon-like peptide-1 drugs, or GLP-1, for treating type 2 diabetes, rose 45% on the year. SALES: Sales rose to DKK41.27 billion from DKK33.04 billion last year and compared with DKK41.57 billion expected in a FactSet poll. NET PROFIT: Net profit in the quarter rose 9.9% to 13.32 billion Danish kroner ($1.82 billion) versus DKK13.63 billion expected in a FactSet poll of analysts.

Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in ...

"Base case all along was for us to continue the trial... Register now for FREE unlimited access to Reuters.com Register now for FREE unlimited access to Reuters.com

Reporting financial results for the first half of 2022 late yesterday, Danish diabetes care giant Novo Nordisk (NOV: N) said that sales increased by 25% in ...

• All the news that moves the needle in pharma and biotech. If your trial has come to an end, you can subscribe here. Novo Nordisk reported second-quarter operating profit of 18.4 billion…

Questions and Answers; Call Participants. Prepared Remarks: Operator. Good evening. This is the conference operator. Welcome, and thank you for joining the ...

We know that it does a trick for both physicians and patients, and we expect that we can get back strongly when we have the products in the market. And in that space, we need to be able to show a differential between the combination therapy and the individual mono components. But basically, the understanding and the perception of GLP-1 in general, as we were taken off and Lars was just talking to the significant growth rate that we have seen underlying the profile of semaglutide. So we believe we have capacity to start rolling out Wegovy in the outside of U.S. And of course, having [Inaudible] the market for a year has underlined the importance of treating people with as – it's also clear that -- [Inaudible] they are suffering from overweight and obese and up to 80% of people living with diabetes, or from obesity. And just to give you an example that I can actually share, for example, for the entire program we are looking at retention rates in excess of 90%, 95%. And that's something similar that you have to imagine for the unit. I know it's only one year ago that you made the initial launch, but it has happened at since then I think that the perception in U.S. has really strengthened that that sampling is the same molecule and maybe you could speculate that many of the patients which have gone on the drug this year is maybe for obesity and maybe the same on mode, do you think that there's actually some change dynamics already now for the obesity potential compared to one year ago, looking at over – since a maybe some of the upside are captured by the so-called GLP-1, diabetes. We do however, also recognize that managing type one diabetes is complex and we still have to work -- we still have work to do on the hypoglycemia risk. And recall last year, we said that we have a benefit, which is less than 3% of US sales, and that still holds for this year, so a number of scenarios to play out. In addition, we also expect to start a Phase 2 trial in the same quarter to explore the potential of higher doses of injectable semaglutide for the treatment of type two diabetes. And in the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. In line with our aspiration to be a sustainable employer, we expanded the number of women in senior leadership positions to 38% compared to 35% by the end of the second quarter of 2021.